http://www.advfn.com/nyse/rss.asp?symbol=AGN Allergan Company Newsfeed en Wed, 01 May 2013 10:15:14 EDT Wed, 01 May 2013 10:15:14 EDT http://www.advfn.com/nyse/StockNews.asp?stocknews=AGN&article=57395614&headline=allergan-1st-quarter-profit-slumps-amid-expected-loss-on-sale http://www.advfn.com/nyse/StockNews.asp?stocknews=AGN&article=57395614&headline=allergan-1st-quarter-profit-slumps-amid-expected-loss-on-sale <div class='newsbody'><pre> By Tess Stynes </pre> <p> Allergan Inc.'s (AGN) first-quarter earnings slumped as the maker of face-wrinkle treatment Botox posted a disposal write-down of $259 million tied to its planned sale of its Lap-Band obesity-prevention unit. </p> <p> Shares were down 3.8% at $109.38... Wed, 01 May 2013 10:15:14 EDT http://www.advfn.com/nyse/StockNews.asp?stocknews=AGN&article=57345604&headline=fda-warns-of-counterfeit-botox http://www.advfn.com/nyse/StockNews.asp?stocknews=AGN&article=57345604&headline=fda-warns-of-counterfeit-botox <div class='newsbody'><pre> By Jennifer Corbett Dooren </pre> <p> WASHINGTON--Federal health authorities have found fake versions of Allergan Inc.'s (AGN) Botox in the U.S. </p> <p> The U.S. Food and Drug Administration said Friday the product may have been distributed to U.S. medical clinics, but so... Fri, 26 Apr 2013 17:37:13 EDT http://www.advfn.com/nyse/StockNews.asp?stocknews=AGN&article=57190433&headline=fda-doesnt-appove-allergans-levadex-for-migraines http://www.advfn.com/nyse/StockNews.asp?stocknews=AGN&article=57190433&headline=fda-doesnt-appove-allergans-levadex-for-migraines <div class='newsbody'><pre> By Tess Stynes </pre> <p> Allergan Inc. (AGN) said the U.S. Food and Drug Adminstration didn't approve its new drug application for its inhalable Levadex treatment for acute migraines in its current form, though the company said it already has taken steps to address some of... Tue, 16 Apr 2013 09:51:35 EDT http://www.advfn.com/nyse/StockNews.asp?stocknews=AGN&article=56639925&headline=allergan-ceos-2012-compensation-up-51-on-performance-and-retention http://www.advfn.com/nyse/StockNews.asp?stocknews=AGN&article=56639925&headline=allergan-ceos-2012-compensation-up-51-on-performance-and-retention <div class='newsbody'><pre> By Peter Loftus </pre> <p> Allergan Inc.'s (AGN) chief executive officer saw a 51% increase in the value of his compensation for 2012 thanks to a large, one-time stock grant intended to reward his performance and to keep him with the medical-products company for another five... Fri, 08 Mar 2013 17:46:09 EST http://www.advfn.com/nyse/StockNews.asp?stocknews=AGN&article=56149543&headline=allergan-4th-quarter-profit-rose-16-amid-growing-revenue-fewer http://www.advfn.com/nyse/StockNews.asp?stocknews=AGN&article=56149543&headline=allergan-4th-quarter-profit-rose-16-amid-growing-revenue-fewer <div class='newsbody'><pre> By Tess Stynes </pre> <p> Allergan Inc.'s (AGN) fourth-quarter earnings rose 16% as the botox-maker reported growing revenue and fewer one-time charges. </p> <p> For the year, the company projected per-share earnings of $4.75 to $4.83, slightly above recent estimates of analysts... Tue, 05 Feb 2013 10:00:42 EST http://www.advfn.com/nyse/StockNews.asp?stocknews=AGN&article=56082082&headline=spectrum-pharma-regains-certain-rights-to-apaziquone http://www.advfn.com/nyse/StockNews.asp?stocknews=AGN&article=56082082&headline=spectrum-pharma-regains-certain-rights-to-apaziquone <div class='newsbody'><pre> By Ben Fox Rubin </pre> <p> Biotechnology firm Spectrum Pharmaceuticals Inc. (SPPI) said it reacquired development and commercialization rights for apaziquone in the U.S., Europe and other territories amid a restructuring of Spectrum's relationship with Allergan Inc. (AGN... Thu, 31 Jan 2013 08:35:34 EST http://www.advfn.com/nyse/StockNews.asp?stocknews=AGN&article=55960461&headline=allergan-looks-to-boost-migraine-sales-with-map-purchase http://www.advfn.com/nyse/StockNews.asp?stocknews=AGN&article=55960461&headline=allergan-looks-to-boost-migraine-sales-with-map-purchase <div class='newsbody'><pre> By Joseph Walker </pre> <p> Botox-maker Allergan Inc. (AGN) doesn't want to be known as just a pretty face. </p> <p> The pharmaceutical firm famous for its cosmetic beauty products has agreed to pay $958 million to purchase MAP Pharmaceuticals Inc. (MAPP), an unproven firm... Wed, 23 Jan 2013 09:01:48 EST http://www.advfn.com/nyse/StockNews.asp?stocknews=AGN&article=55951640&headline=allergan-to-buy-map-pharmaceuticals-for-958-million http://www.advfn.com/nyse/StockNews.asp?stocknews=AGN&article=55951640&headline=allergan-to-buy-map-pharmaceuticals-for-958-million <div class='newsbody'><p> Allergan Inc. (AGN) said Tuesday it will buy MAP Pharmaceuticals Inc. (MAPP) in a $958 million deal that would help the Botox maker expand sales of medical treatments. </p> <p> The cash deal, for $25 a share or a 60% premium, comes after the two companies had agreed to jointly... Tue, 22 Jan 2013 22:40:11 EST http://www.advfn.com/nyse/StockNews.asp?stocknews=AGN&article=55913317&headline=fda-expands-approval-of-botox-to-treat-overactive-bladder http://www.advfn.com/nyse/StockNews.asp?stocknews=AGN&article=55913317&headline=fda-expands-approval-of-botox-to-treat-overactive-bladder <div class='newsbody'><pre> By Kristin Jones </pre> <p> The U.S. Food and Drug Administration has expanded the approved use of Allergan Inc.'s (AGN) Botox to treat adults with overactive bladders who don't respond to other medications. </p> <p> The regulatory agency said Botox can be used to treat patients... Fri, 18 Jan 2013 17:31:30 EST http://www.advfn.com/nyse/StockNews.asp?stocknews=AGN&article=55753499&headline=allergan-ceo-pyott-company-plans-to-sell-weight-loss-division http://www.advfn.com/nyse/StockNews.asp?stocknews=AGN&article=55753499&headline=allergan-ceo-pyott-company-plans-to-sell-weight-loss-division <div class='newsbody'><p> Allergan Inc. (AGN) Chief Executive David Pyott said the company has received "a lot of interest" for its weight-loss division, which includes the Lap-Band product, Bloomberg News reported Tuesday. </p> <p> Mr. Pyott told Bloomberg that Allergan expects to sell the business... Tue, 08 Jan 2013 14:19:23 EST http://www.advfn.com/nyse/StockNews.asp?stocknews=AGN&article=55065371&headline=allergan-to-buy-skinmedica-for-350-million http://www.advfn.com/nyse/StockNews.asp?stocknews=AGN&article=55065371&headline=allergan-to-buy-skinmedica-for-350-million <div class='newsbody'><pre> By Ben Fox Rubin </pre> <p> Allergan Inc. (AGN) said it agreed to buy SkinMedica Inc.'s topical-aesthetics skin-care business for $350 million to increase its presence in the skin-care market. </p> <p> The deal includes an additional $25 million in payments, dependent on the... Fri, 16 Nov 2012 10:15:15 EST http://www.advfn.com/nyse/StockNews.asp?stocknews=AGN&article=54929259&headline=cvs-pbm-business-names-drugs-it-plans-to-block-next-year http://www.advfn.com/nyse/StockNews.asp?stocknews=AGN&article=54929259&headline=cvs-pbm-business-names-drugs-it-plans-to-block-next-year <div class='newsbody'><pre> By Jon Kamp and Peter Loftus </pre> <p> CVS Caremark Corp.'s (CVS) pharmacy-benefit business is taking aim at certain treatments for low testosterone and glaucoma, among other conditions, in its latest push to steer members away from what it says are expensive drugs with available... Thu, 08 Nov 2012 13:33:36 EST http://www.advfn.com/nyse/StockNews.asp?stocknews=AGN&article=54746248&headline=allergan-3rd-quarter-profit-edges-down-weighs-options-for-obesity http://www.advfn.com/nyse/StockNews.asp?stocknews=AGN&article=54746248&headline=allergan-3rd-quarter-profit-edges-down-weighs-options-for-obesity <div class='newsbody'><pre> By Tess Stynes </pre> <p> Allergan Inc.'s (AGN) third-quarter earnings edged down slightly as the maker of Botox and medical devices posted more one-time items, masking continued sales growth for top drug Botox. </p> <p> Since the end of the quarter, Allergan said it is exploring... Tue, 30 Oct 2012 11:48:54 EDT http://www.advfn.com/nyse/StockNews.asp?stocknews=AGN&article=54502252&headline=watson-pharmaceuticals-gains-fda-approval-for-two-generics http://www.advfn.com/nyse/StockNews.asp?stocknews=AGN&article=54502252&headline=watson-pharmaceuticals-gains-fda-approval-for-two-generics <div class='newsbody'><pre> By Ben Fox Rubin </pre> <p> Watson Pharmaceuticals Inc. (WPI) said it received approval from the U.S. Food and Drug Administration for the generic version of Sanofi's (SNY) Avapro. </p> <p> Avapro, the brand name for Irbesartan, is used for high blood pressure and for kidney... Fri, 12 Oct 2012 17:05:43 EDT http://www.advfn.com/nyse/StockNews.asp?stocknews=AGN&article=53891381&headline=allergan-signs-ophthalmic-drug-development-pacts-with-molecular http://www.advfn.com/nyse/StockNews.asp?stocknews=AGN&article=53891381&headline=allergan-signs-ophthalmic-drug-development-pacts-with-molecular <div class='newsbody'><pre> By Saabira Chaudhuri </pre> <p> Allergan Inc. (AGN) signed agreements with privately owned biotechnology firm Molecular Partners AG to develop and commercialize a class of biological drugs for the treatment of serious ophthalmic diseases. </p> <p> Called DARPins, the drugs... Tue, 21 Aug 2012 07:13:36 EDT http://www.advfn.com/nyse/StockNews.asp?stocknews=AGN&article=53673495&headline=allergan-2nd-quarter-profit-up-20-3q-eps-view-misses-estimates http://www.advfn.com/nyse/StockNews.asp?stocknews=AGN&article=53673495&headline=allergan-2nd-quarter-profit-up-20-3q-eps-view-misses-estimates <div class='newsbody'><pre> By Tess Stynes </pre> <p> Allergan Inc.'s (AGN) second-quarter earnings rose 20% though a strong dollar weighed on revenue growth at the maker of Botox and medical devices. </p> <p> For the year, the company narrowed its guidance and now expects per-share earnings of $4.15... Wed, 01 Aug 2012 10:11:11 EDT http://www.advfn.com/nyse/StockNews.asp?stocknews=AGN&article=52877303&headline=map-pharmaceuticals-to-resubmit-application-for-migraine-treatment http://www.advfn.com/nyse/StockNews.asp?stocknews=AGN&article=52877303&headline=map-pharmaceuticals-to-resubmit-application-for-migraine-treatment <div class='newsbody'><pre> By Victoria Stilwell </pre> <p> MAP Pharmaceuticals Inc. (MAPP) said it plans to resubmit its new drug application for acute migraine treatment Levadex by the late third quarter or early fourth quarter after meeting with the U.S. Food and Drug Administration. </p> <p> The... Mon, 25 Jun 2012 08:07:14 EDT http://www.advfn.com/nyse/StockNews.asp?stocknews=AGN&article=52373719&headline=uks-nice-backs-allergans-botox-for-some-migraine-sufferers http://www.advfn.com/nyse/StockNews.asp?stocknews=AGN&article=52373719&headline=uks-nice-backs-allergans-botox-for-some-migraine-sufferers <div class='newsbody'><p> LONDON -(Dow Jones)- The cost regulator for the U.K.'s publicly-funded National Health Service has reversed its earlier stance on U.S.-based Allergan Inc.'s (AGN) wrinkle-fighting drug Botox and now recommends its use for some patients suffering from migraine headaches. </p> <p>... Fri, 11 May 2012 05:08:23 EDT http://www.advfn.com/nyse/StockNews.asp?stocknews=AGN&article=52310112&headline=allergan-gets-subpoena-from-government-over-lap-band-system http://www.advfn.com/nyse/StockNews.asp?stocknews=AGN&article=52310112&headline=allergan-gets-subpoena-from-government-over-lap-band-system <div class='newsbody'><pre> By Anjali Athavaley Of DOW JONES NEWSWIRES </pre> <p> NEW YORK -(Dow Jones)- Allergan Inc. (AGN) received a subpoena this month from the Department of Health and Human Services requesting documents related to the company's Lap-Band System for obesity, according to a filing... Mon, 07 May 2012 18:26:10 EDT http://www.advfn.com/nyse/StockNews.asp?stocknews=AGN&article=52250340&headline=allergan-1q-profit-rose-45-on-stronger-specialty-drug-sales http://www.advfn.com/nyse/StockNews.asp?stocknews=AGN&article=52250340&headline=allergan-1q-profit-rose-45-on-stronger-specialty-drug-sales <div class='newsbody'><p> DOW JONES NEWSWIRES </p> <p> Allergan Inc.'s (AGN) first-quarter earnings rose 45% as the maker of Botox and medical devices reported double-digit sales growth at its specialty pharmaceuticals business. </p> <p> The company projected second-quarter results below analysts' expectations... Wed, 02 May 2012 10:05:35 EDT